Evidence map›Paper›PMID 39777612›Full record

ArticleMolecular diagnosis & therapy2025

The Role of [

Daniele Antonio Pizzuto, Angelo Castello, Marco Chiappetta, Massimo Castellani, Salvatore Annunziata, Annalisa Campanella, Giuseppe Calabrese, Margherita Cattaneo, Lorenzo Rosso, Giacomo Cusumano and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diagnosis & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. [Cancers · 2026
    Article
  2. Article
  3. The Value of Baseline [Diagnostics (Basel, Switzerland) · 2025
    Review
  4. Machine Learning Models Derived from [Bioengineering (Basel, Switzerland) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Daniele Antonio Pizzuto *Nuclear Medicine Unit, GSTeP Radiopharmacy-TracerGLab, Department of Radiology, Radiotherapy and Hematology, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168, Rome, Italy.
Angelo Castello *Department of Nuclear Medicine, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, 20122, Milan, Italy.
Marco ChiappettaThoracic Surgery, Università Magna Graecia, Catanzaro, Italy. marco.chiappetta@policlinicogemelli.it.
Massimo CastellaniDepartment of Nuclear Medicine, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, 20122, Milan, Italy.
Salvatore AnnunziataNuclear Medicine Unit, GSTeP Radiopharmacy-TracerGLab, Department of Radiology, Radiotherapy and Hematology, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168, Rome, Italy.
Annalisa CampanellaDepartment of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, 00168, Rome, Italy.
Giuseppe CalabreseDepartment of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, 00168, Rome, Italy.
Margherita CattaneoThoracic Surgery and Lung Transplantation, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, 20122, Milan, Italy.
Lorenzo RossoThoracic Surgery and Lung Transplantation, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, 20122, Milan, Italy.
Giacomo CusumanoGeneral Thoracic Surgery Unit, Azienda Ospedaliero Universitaria Policlinico "G. Rodolico-San Marco", 95100, Catania, Italy.
Filippo Lococo *Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, 00168, Rome, Italy.
Paolo Mendogni *Thoracic Surgery and Lung Transplantation, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, 20122, Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo investigate whether 18F-fluorodeoxyglucose positron emission tomography-computed tomography ([ PATIENTS AND

methodsIn total, 116 patients (49/67 M/F; mean age 59.5 years) who underwent preoperative [

resultsIn total, 27 thymic hyperplasia, 41 low-risk thymomas (LRT) (types A, AB, and B1), and 48 high-risk thymomas (HRT) (B2, B3 thymoma, and carcinoma) were included. SUVmax, SUVmean, SUVpeak, rPET, qPET, and T/M were significantly higher in HRT than LRT and hyperplasia (p < 0.001). TLG and MTV were significantly higher in patients with LRT (p < 0.001). Only rPET, qPET, and T/M remained significantly higher in HRT than in LRT subgroups (p = 0.042, p = 0.049, and p = 0.028, respectively). SUVmax, SUVmean, and SUVpeak cutoffs of < 4.3, < 2.87, and 4.03, respectively, significantly distinguished patients with longer FFR (p = 0.009, p = 0.05, and p = 0.05).

conclusionsPositron emission tomography (PET) metabolic parameters could help to differentiate thymic histotypes. Standardized uptake value (SUV)-based parameters appear promising to predict recurrent disease.

Indexed as

Fluorodeoxyglucose F18Positron Emission Tomography Computed TomographyThymomaThymus NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedPrognosisRadiopharmaceuticalsRetrospective StudiesFluorodeoxyglucose F18Radiopharmaceuticals

Identifiers

PMID39777612

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.